Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Bone

IGFBP1—hepatokine and target for FGF21-mediated bone loss

Nature Reviews Endocrinology volume 11, page 690 (2015)Cite this article

Subjects

Access through your institution
Buy or subscribe

Wang and co-workers found that mouse liver cells secrete a factor that promotes osteoclast differentiation; this secretion is enhanced by overexpression of FGF21. The liver factor was identified as IGFBP1—osteoclastogenesis was inhibited by an anti-IGFBP1 antibody, and stimulated by murine and human recombinant IGFBP1.

IGFBP1 is highly expressed in the liver, and this expression is responsive to levels of FGF21. In vivo administration of IGFBP1 was found to increase bone resorption in wild-type mice. Administration of anti-IGFBP1 antibody to mice overexpressing FGF21 reduced the elevated bone loss seen in these animals to wild-type levels, but did not affect the FGF21-mediated improvement in insulin sensitivity.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wang, X. et al. A liver–bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption Cell Metab. 22, 1–14 (2015)

    Article  Google Scholar 

Download references

Authors
  1. Robert Phillips
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Phillips, R. IGFBP1—hepatokine and target for FGF21-mediated bone loss. Nat Rev Endocrinol 11, 690 (2015). https://doi.org/10.1038/nrendo.2015.187

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrendo.2015.187

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing